| abstract |
There is disclosed a pharmaceutical composition exhibiting H2-antagonistic activities and/or activities against Helicobacter pyroli in a solid unit dosage adapted for oral administration, which contains 50 - 95 percent by weight of a salt formed between ranitidine and a complex of bismuth with a carboxylic acid selected from tartaric acid and citric acid together 2 - 20 percent by weight of an alkaline salt with the proviso that said alkaline salt is an alk. metal carbonate or alk. earth metal carbonate or hydrogen carbonate, or a mixture thereof. Preferably, the composition is in tablet form and comprises ranitidine bismuth citrate and sodium carbonate. The composition shows improved disintegration and/or dissolution. |